


What is claimed is:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof,



wherein


R_1 is selected from C_{1-6} alkylthio, 5-6 membered heteroaryl, C_{2-6} alkynyl and C_{3-6} cycloalkyl each of which is optionally substituted with 1, 2 or 3 R or R';


T_1 is selected from N or CH;

T_2 is selected from N or C(R_2);

R_2 is selected from H, F, Cl, Br, I;

R_3 is selected from H, halogen, CN, NH_2 , OH, or from C_{1-6} alkyl which is optionally substituted with 1, 2 or 3 R or R';


R is selected from halogen, OH, NH_2 , CN, COOH, , or from C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl, 3-6 membered heterocycloalkyl-C(=O)-, 3-6 membered heterocycloalkyl-(CH₂)₁₋₃- each of which is optionally substituted with 1, 2 or 3 R';

R' is selected from F, Cl, Br, I, CN, OH, NH_2 , COOH, Me, $NHCH_3$, $N(CH_3)_2$, ,
or  ;


“hetero-” in the 5-6 membered heteroaryl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, 3-6 membered heterocycloalkyl is selected from -N=, -S-, -O-, or -NH-;

in any one of the aforesaid cases, the number of heteroatom(s) or heteroatomic group(s) is each independently selected from 1, 2 or 3,


wherein the compound of formula (I) is not a compound selected from the group




2. The compound or the pharmaceutically acceptable salt thereof according to claim 1,





wherein, R is selected from F, Cl, Br, I, OH, NH₂, CN, COOH, , or from C₁₋₃ alkyl, C₁₋₃ heteroalkyl, C₃₋₆ cycloalkyl, 3-6 membered heterocycloalkyl, 3-6 membered heterocycloalkyl-C(=O)-, 3-6 membered heterocycloalkyl-CH₂- each of which is optionally substituted with 1, 2 or 3 R'.

3. The compound or the pharmaceutically acceptable salt thereof according to claim 1,


wherein, R is selected from F, Cl, Br, I, OH, NH₂, CN, COOH, , or from Me, Et, C₁₋₃ alkylthio, C₃₋₆ cycloalkyl, azetidiny, pyrrolidinyl, piperazinyl, morpholinyl, piperazinyl-C(=O)-, morpholinyl-C(=O)-, pyrrolidinyl-C(=O)-, piperazinyl-CH₂-, morpholinyl-CH₂-, pyrrolidinyl-CH₂- each of which is optionally substituted with 1, 2 or 3 R'.






4. The compound or the pharmaceutically acceptable salt thereof according to claim 3,





wherein, R is selected from F, Cl, Br, I, OH, NH₂, CN, COOH, , or from Me,

Et, , , , , , ,  each of which is optionally substituted with 1, 2 or 3 R'.

5. The compound or the pharmaceutically acceptable salt thereof according to claim 4,



wherein, R is selected from F, Cl, Br, I, OH, NH₂, Me, Et, CN, COOH, , ,

, , , , , , , ,





, , , , , or .







6. The compound or the pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, R₁ is selected from C₁₋₃ alkylthio, C₂₋₄ alkynyl, C₃₋₅ cycloalkyl each of which is optionally substituted with 1, 2 or 3 R or R'.

7. The compound or the pharmaceutically acceptable salt thereof according to claim 6,

wherein, R₁ is selected from , , , , or  each of which is optionally substituted with 1, 2 or 3 R or R'.

8. The compound or the pharmaceutically acceptable salt thereof according to claim 7,

wherein, R₁ is selected from , , , , ,

, , , , , , , , , or





9. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, R_1 is selected from pyridyl, pyrazolyl, imidazolyl, thienyl, oxazolyl, isoxazolyl each of which is optionally substituted with 1, 2 or 3 R or R' .

10. The compound or the pharmaceutically acceptable salt thereof according to claim


9, wherein, R_1 is selected from , , , , , , , or  each of which is optionally substituted with 1, 2 or 3 R or R' .

11. The compound or the pharmaceutically acceptable salt thereof according to claim

10, wherein, R_1 is selected from , , , , , , , , , , , , , , , , , , , , , , , , , , , 



12. The compound or the pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, R_1 is selected from




13. The compound or the pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, T_2 is selected from N, CH or C(F).

14. The compound or the pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, R₃ is selected from H, halogen, CN, NH₂, OH, or from C₁₋₃ alkyl which is optionally substituted with 1, 2 or 3 R or R'.


15. The compound or the pharmaceutically acceptable salt thereof according to claim 14, wherein, R₃ is selected from H, F, Cl, Br, I, CN, NH₂, OH, or from Me and Et each of which is optionally substituted with 1, 2 or 3 R or R'.


16. The compound or the pharmaceutically acceptable salt thereof according to claim 15, wherein, R₃ is selected from H, F, Cl, Br, I, CN, NH₂, OH, Me, Et, or CF₃.

17. The compound or the pharmaceutically acceptable salt thereof according to any one




18. The compound or the pharmaceutically acceptable salt thereof according to any one of claim 1-17, which is selected from








wherein, R₁ and R₃ are as defined in any one of claims 1-17.

19. A compound represented by a formula selected from









or a pharmaceutically acceptable salt thereof.

20. A compound represented by a formula selected from

